Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19

BACKGROUND: Limited therapeutic options exist for coronavirus disease 2019 (COVID-19). COVID-19 convalescent plasma (CCP) is a potential therapeutic, but there is limited data for patients with moderate-to-severe disease. RESEARCH QUESTION: What are outcomes associated with administration of CCP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Briggs, Neima, Gormally, Michael V., Li, Fangyong, Browning, Sabrina L., Treggiari, Miriam M., Morrison, Alyssa, Laurent-Rolle, Maudry, Deng, Yanhong, Hendrickson, Jeanne E., Tormey, Christopher A., Desruisseaux, Mahalia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318280/
https://www.ncbi.nlm.nih.gov/pubmed/34320004
http://dx.doi.org/10.1371/journal.pone.0254453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318280/
https://www.ncbi.nlm.nih.gov/pubmed/34320004
http://dx.doi.org/10.1371/journal.pone.0254453

Ejemplares similares